Nature Medicine

10/23/2026

News & Views: New studies of trends in the global burden of and offer a reminder of how much vaccination has achieved, and a warning of the need for more resilient and sustainable vaccination programs.

New studies of trends in the global burden of measles and pertussis offer a reminder of how much vaccination has achieved and a warning of the need to build more resilient and sustainable vaccination programs.

10/23/2026

Ed Summ: As presented at the ESMO Congress 2026: In a randomized phase 2 trial evaluating an off-the-shelf, lymph node-targeting peptide vaccine in patients with mKRAS PDAC within 6 months of standard curative intent therapy, the primary endpoint of disease-free survival was not met but prespecified subgroup analyses showed that significant disease-free survival was seen in the vaccine arm for patients with ctDNA negative disease without prior radiation treatment http://dlvr.it/TW27MP

10/23/2026

As presented at the ESMO Congress 2026: In a phase 1/2 trial in patients with solid tumors, a first-in-class bispecific agonistic antibody that selectively targets the prevalent Vβ6/Vβ10 T cell subsets was well tolerated, enabling the selection of a recommended phase 2 dose for further testing, and showed a preliminary efficacy signal in both immunologically hot and cold tumors http://dlvr.it/TW276c

10/22/2026

News & Views: A small study shows that patients with can help fine-tune their own seizure detectors by chatting with an agent. However, the more difficult challenge ahead is to build AI that responds appropriately.

A small study shows that patients can help fine-tune their own seizure detectors by chatting with an AI agent. However, the more difficult challenge ahead is to build AI that responds appropriately.

10/22/2026

The liver can warn us of metabolic dysfunction long before serious disease develops. So why do we wait until people are “sick enough” to act?

Jeffrey V. Lazarus argues for earlier action in a new World View.
Read the article:

The liver can warn us of metabolic dysfunction long before serious consequences emerge. Why aren’t we listening?

10/22/2026

News & Views: A secondary analysis of trial data shows that both host antibodies and infused antibodies against help to delay viral rebound after interruption of antiretroviral therapy (ART), which could inform approaches to durable, ART-free HIV control.

A secondary analysis of trial data shows that both host antibodies and infused antibodies against HIV help to delay viral rebound after interruption of antiretroviral therapy (ART), which could inform approaches to durable, ART-free HIV control.

10/21/2026

A new study tackles issues around operational and decisional trust of , using locally deployed, on-premise agents and consistency-based gating to refer uncertain cases — but what happens after referral remains untested.
News & Views from Mahmud Omar & colleagues

A new study tackles issues around operational and decisional trust of agentic artificial intelligence (AI), using locally deployed, on-premise agents and consistency-based gating to refer uncertain cases — but what happens after referral remains untested.

10/19/2026

In a randomised multicenter phase 2 trial, patients with high-volume metastatic hormone sensitive prostate cancer treated with PARP inhibitor talazoparib combined with androgen receptor inhibitor enzalutamide had an improved PSA response compared with enzalutamide alone.

In the randomized multicenter phase 2 ZZ-FIRST trial, patients with high-volume metastatic hormone-sensitive prostate cancer treated with poly(ADP-ribose) polymerase inhibitor talazoparib combined with androgen receptor inhibitor enzalutamide had an improved prostate-specific antigen response compar...

10/16/2026

A phase 1 trial shows that treatment of patients with high-grade serous ovarian cancer with personalized neoantigen vaccines combined with PD-1 blockade was feasible and led to tumor-specific immune responses in many patients and putative mechanisms of resistance related to antigen presentation were identified via cell-free DNA analysis.